Phase 2 Clinical Trial Progress Update

CRISM Therapeutics Corporation

25 June 2026

 

The information contained within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014, as incorporated into UK law by the European Union (Withdrawal) Act 2018. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

25 June 2026

CRISM Therapeutics Corporation

("CRISM", "CRISM Therapeutics" or the "Company")

Phase 2 Clinical Trial Progress Update

CRISM Therapeutics Corporation (AIM: CRTX), a UK clinical-stage drug delivery company focused on the localised and sustained delivery of chemotherapy drugs, provides an update on its Phase 2 clinical trial of irinotecan ChemoSeed® in patients with glioblastoma.

The Company confirms that all product manufacturing, quality, regulatory and study start-up activities required for patient treatment have been completed and that site activation is at an advanced stage.  Multiple clinical support departments have completed their individual assessments and sign-off procedures, and a Site Initiation Visit ("SIV"), the final procedural step before the site can be activated for patient recruitment, is planned for late July. This represents significant progress and the Company will provide further updates regarding patient recruitment and dosing following the SIV.

The Company is fully funded to complete Part 1 of the trial and is well positioned to initiate Part 2 on completion. The Board looks forward to providing shareholders with further updates regarding the trial and the clinical development of ChemoSeed in due course.

-Ends-

Enquiries:

Company	Nomad and Broker	Financial PR
CRISM Therapeutics Corporation	S.P. Angel Corporate Finance LLP	Burson Buchanan
Andrew Webb, Executive Chairman Chris McConville, CSO	David Hignell Vadim Alexandre Adam Cowl	Henry Harrison Topham Jamie Hooper [e-mail]
via Burson Buchanan	[phone]	[phone]

About CRISM Therapeutics Corporation

CRISM Therapeutics Corporation has developed an innovative drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs.

ChemoSeed, CRISM's lead product, can be implanted directly into the tumour or the resection margin following the removal of a tumour. This directs that therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour tissue or cover the entire resection margin. In the case of treating glioblastoma, ChemoSeeds can be implanted during surgery thereby bypassing the blood brain barrier, which prevents other treatments from being able to reach the tumour and be effective.

For more information please visit: https://www.crismtherapeutics.com/

The Company's LEI is 213800XFW6MKVCHHPW88.

 

END